DelveInsight's 'Retinal Vein Occlusion (RVO)-Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical and forecasted RVO epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.
Retinal Vein Occlusion (RVO) Understanding
Retinal vein occlusion, one of the most frequently occurring retinal vascular disorders in elderly patients, develops predominantly in individuals over age 65 years. The main risk factors for RVO include age and systemic vascular disorders.It is categorized into central RVO (CRVO) and branch RVO (BRVO) according to the site of blockage in the retinal vein. CRVO is divided further into nonischemic and ischemic types according to the perfusion status based on fluorescein angiography. BRVO consists of major branch RVO (when one of the major branch retinal veins is occluded, usually near, or rarely at, the optic disc) and macular branch RVO (when only one of the macular venules is occluded). Macular edema is the major complication of significant visual loss in patients with CRVO and BRVO, and various treatments have been used to improve macular edema and cause regression of intraocular neovascularization.
The initial examination of a patient with an RVO includes all relevant aspects of the comprehensive adult medical eye evaluation, with particular attention to those aspects related to retinal vascular disease. Several tests are being used for the diagnosis of RVO such as Optical coherence tomography (OCT), and fluorescein angiography (FA). Apart from this, Systemic evaluation is often performed in patients with CRVO and is directed by the patient's age, coexisting risk factors, and medical history. In RVO, intravitreal steroids and anti-VEGF therapy are used in cases of macular perfusion and macular ischemia, with the laser of use in situations of neovascularization. Response to treatment may be measured by improvement of visual acuity (as a measure of photoreceptor status) and retinal thickness (as a measure of leakage).
Retinal Vein Occlusion Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of RVO, Diagnosed Prevalent Cases of RVO, Gender-specific Diagnosed Prevalent Cases of RVO, Age-specific Diagnosed Prevalent Cases of RVO, Type-specific Diagnosed Prevalent Cases of RVO, and Treated Cases of RVO in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
RVO Detailed Epidemiology Segmentation
- In the year 2017, the total prevalent cases of RVO were 2,225,011 cases in the 7MM, which is expected to increase in the forecast period.
- The United States, in 2017, accounted for 1,124,718 cases prevalent cases of RVO (the highest number), which will probably rise in the year 2030. In EU-5 countries the highest number of prevalent Cases of RVO was in Germany, i.e., 206,690, in the year 2017. The lowest number of cases observed in Spain during the study period.
- In 2017, the total diagnosed prevalent cases of RVO in the 7MM were 1,947,496.
- In the 7MM, the total gender-specific prevalent cases of RVO were 916,868 for males and 1,030,628 for females in the year 2017
- RVO is more frequent in the older age population. Hence, in the 7MM, the total diagnosed cases of RVO by age distribution were 1,124,790, 516,151, and 306,555 cases for the age group less than 65 years, 65-74 years, and ≥75 years, in 2017.
- In the 7MM, CRVO contributed to 392,221 cases in 2017, and there were around 1,555,274 BRVO cases, the same year.
Scope of the Report:
- The report covers the descriptive overview of RVO, explaining its causes, signs, and symptoms, and pathophysiology.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
- The report assesses the disease risk and burden.
- The report provides the segmentation of the disease epidemiology for 7MM by Prevalent Cases, Diagnosed Prevalent Cases, Ender-Specific Diagnosed Prevalent Cases, Age-Specific Diagnosed Prevalent Cases, Type-Specific Diagnosed Prevalent Cases And Treated Cases.
- 11-Year Forecast of RVO
- 7MM Coverage of RVO
- Prevalent Cases of RVO in the 7MM
- Diagnosed Prevalent Cases of RVO in the 7MM
- Gender-specific Diagnosed Prevalent Cases of RVO in the 7MM
- Age-specific Diagnosed Prevalent Cases of RVO in the 7MM
- Type-specific Diagnosed Prevalent Cases of RVO in the 7MM
- Treated Cases of RVO in the 7MM
Key Questions Answered
- What are the disease risk, burden, and unmet needs of RVO?
- What is the historical RVO patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of RVO at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to RVO?
- Out of the countries mentioned above, which country would have the highest incident population of RVO during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Reasons to buy:
The RVO report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM RVO market.
- Quantify patient populations in the 7MM RVO market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the specific type of RVO that presents the best opportunities for RVO therapeutics in each of the markets covered.
- The RVO epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
- The RVO epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030